Cargando…

Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications

Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardestani, Mina, Khorsandi, Zahra, Keshavarzipour, Fariba, Iravani, Siavash, Sadeghi-Aliabadi, Hojjat, Varma, Rajender S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610671/
https://www.ncbi.nlm.nih.gov/pubmed/36297655
http://dx.doi.org/10.3390/pharmaceutics14102220
_version_ 1784819334165561344
author Ardestani, Mina
Khorsandi, Zahra
Keshavarzipour, Fariba
Iravani, Siavash
Sadeghi-Aliabadi, Hojjat
Varma, Rajender S.
author_facet Ardestani, Mina
Khorsandi, Zahra
Keshavarzipour, Fariba
Iravani, Siavash
Sadeghi-Aliabadi, Hojjat
Varma, Rajender S.
author_sort Ardestani, Mina
collection PubMed
description Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors. Herein, recently synthesized heterocyclic compounds recognized as potent Hsp90 inhibitors are reviewed along with the anticancer effects of heterocyclic compounds, comprising purine, pyrazole, triazine, quinolines, coumarin, and isoxazoles molecules.
format Online
Article
Text
id pubmed-9610671
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96106712022-10-28 Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications Ardestani, Mina Khorsandi, Zahra Keshavarzipour, Fariba Iravani, Siavash Sadeghi-Aliabadi, Hojjat Varma, Rajender S. Pharmaceutics Review Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors. Herein, recently synthesized heterocyclic compounds recognized as potent Hsp90 inhibitors are reviewed along with the anticancer effects of heterocyclic compounds, comprising purine, pyrazole, triazine, quinolines, coumarin, and isoxazoles molecules. MDPI 2022-10-18 /pmc/articles/PMC9610671/ /pubmed/36297655 http://dx.doi.org/10.3390/pharmaceutics14102220 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ardestani, Mina
Khorsandi, Zahra
Keshavarzipour, Fariba
Iravani, Siavash
Sadeghi-Aliabadi, Hojjat
Varma, Rajender S.
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
title Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
title_full Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
title_fullStr Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
title_full_unstemmed Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
title_short Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
title_sort heterocyclic compounds as hsp90 inhibitors: a perspective on anticancer applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610671/
https://www.ncbi.nlm.nih.gov/pubmed/36297655
http://dx.doi.org/10.3390/pharmaceutics14102220
work_keys_str_mv AT ardestanimina heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications
AT khorsandizahra heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications
AT keshavarzipourfariba heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications
AT iravanisiavash heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications
AT sadeghialiabadihojjat heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications
AT varmarajenders heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications